Treatment of Complex Cutaneous Leishmaniasis with Liposomal Amphotericin B
María Ubals, Pau Bosch‐Nicolau, Adrián Sánchez‐Montalvá, Fernando Salvador, Gloria Aparicio-Español, Elena Sulleiro, Aroa Silgado, Antoni Soriano‐Arandes, María Espiau, Berta Ferrer-Rosell, Diana Pou, Begoña Treviño, Israel Molina, Vicente García‐Patos
Abstract
BACKGROUND: There is no consensus for the best treatment of complex cutaneous leishmaniasis (CL). We aimed to describe a cohort of CL, focusing on liposomal amphotericin B (L-AmB) treatment outcome. METHODS: We performed a retrospective study in Vall d'Hebron University Hospital (Barcelona, Spain). All patients with parasitologically proven CL diagnosed from 2012 to 2018 were included. RESULTS: The analysis included 41 patients with CL. The median age was 39 years (IQR 12- 66); 12 (29%) were children, and 29 (71%) were men. Regarding treatment, 24 (59%) received local treatment, whereas 17 (41%) had complex CL and were offered intravenous systemic treatment. Sixteen patients received L-AmB; eight (50%) had adverse events, and three (19%) discontinued treatment for safety reasons. All cases were considered cured within the first year post-treatment. CONCLUSIONS: L-AmB for complex CL showed no treatment failures, offering an alternative treatment option for patients with complex CL. Clinicians should pay close attention to the potential adverse events of L-AmB and adopt an active drug safety surveillance scheme to rapidly detect reversible side effects.